Wednesday, February 5, 2025

QLS-111 Demonstrates Efficacy in Trials

Qlaris Bio reports positive phase 2 results for its investigational drug treatment QLS-111 in glaucoma and OHT patients.

Wednesday, February 5, 2025

Iantrek Appoints New CEO

Adam Szaronos takes over top leadership role from company founder Dr. Sean Ianchulev, who will remain involved as board chair and CMO.

Monday, February 3, 2025

BVI Medical Launches Educational Platform for Ophthalmic Surgeons

EyeXchange Solutions connects experienced and emerging surgeons across cataract, glaucoma, and retina specialties to share insights, refine techniques, and address complex cases. 

Thursday, January 23, 2025

AMA Prior Authorization Statement

The American Medical Association comments on a recent statement by US insurer UnitedHealth that it will work toward easing prior authorization rules.

Wednesday, January 22, 2025

Heidelberg Symposium to Showcase Glaucoma Innovations

The event will highlight the growing role of artificial intelligence in glaucoma diagnosis and management.

Tuesday, January 14, 2025

Bausch + Lomb, Glaucoma Research Foundation Launch Second Annual ‘Faces of Glaucoma’ Campaign and Fundraising Challenge

Throughout January, Bausch + Lomb and Glaucoma Research Foundation will spotlight educational resources and share stories of individuals and families living with glaucoma to raise awareness of the disease.

Monday, January 13, 2025

Bausch + Lomb Acquires Whitecap Biosciences

With innovative therapies addressing glaucoma and geographic atrophy currently in development, the acquisition of Whitecap Bioscience's strengthens B + L’s expanding clinical-stage pipeline. 

Tuesday, January 7, 2025

Canyon Labs Acquires iuvo BioScience’s Lab Division

The deal allows each company to focus on strengths.